Synteract is a uniquely positioned CRO partner effective in navigating the challenges of clinical development to help bring new medicines to market. By applying the same disciplined, strategic assessment and decision-making processes used across other areas of development, Synteract can implement the robust cross-therapeutic expertise we have acquired over our 30-year history to advance the needs of small biotech and mid-sized biopharma.

Although diabetes remains as the leading endocrine diagnosis in the United States, we recognize that this is just one in a sea of many indications needing to be addressed. Our team of experts understand the endocrine system and how even the slightest shift in function can cause a potentially life-threatening imbalance that could affect growth and development, metabolism – including digestion, elimination, breathing, blood circulation, and body temperature, reproduction, sexual function, and more.

We have acquired a wealth of global trial experience across a variety of endocrine and metabolic indications such as arginase deficiency, congenital hyperinsulinism, diabetes (type 1 & 2, including diabetic neuropathy pain), growth hormone deficiency, hypogonadism, urea cycle disorders, and more.